HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for ...
Backed by more than 30 peer-reviewed human clinical studies supporting endogenous antioxidant activity, cellular ...
LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, announced that it has successfully closed its first fundraising ...
KANAGAWA, Japan & LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, Inc., a US pharmaceutical company developing novel therapeutics for ophthalmic and dermal diseases, and SCOHIA PHARMA, Inc, a ...
C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.
Breaking News: Holiday special – 25% off BioWorld subscriptions Home » Fundraising at Kuria Therapeutics to advance topical ophthalmic Nrf2 activator Upgrade your daily dose of biopharma and medtech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results